transplant

FDA delays decision on Orca Bio’s cell therapy for blood cancers

The delay comes at a time when the biopharma industry is highly attuned to FDA actions on cell and gene therapies after a string of regulatory surprises.

Angus Liu Apr 1, 2026 8:00am

FDA signs off on Omeros' stem cell transplant drug Yartemlea

Dec 26, 2025 12:46pm

Hansa eyes FDA filing after ph. 3 win for kidney transplant med

Sep 25, 2025 12:37pm

AZ touts Ultomiris results in post-transplant complication trial

Jun 16, 2025 10:32am

BMS's Orencia wins FDA nod for prevention of GVHD

Dec 15, 2021 3:25pm

BMS' Orencia snagged priority review in transplant rejection

Aug 23, 2021 11:02am